Anaplastic thyroid cancer

Rohit Ranganath, Manish A. Shah, Ashok R. Shah

Research output: Contribution to journalReview article

Abstract

Purpose of review Anaplastic thyroid cancer (ATC) is a rare malignancy of the thyroid with a high mortality rate. Conventional therapy has not been effective. Several biological agents are being investigated. The purpose of the review is to highlight the current standards for treatment and review new targets for treating ATC. Recent findings Retrospective studies have led to formulation of guidelines for management, including those by the American Thyroid Association. An expansion in the understanding of the genetic mutations has led to several newer biological agents being tested to treat ATC. Aurora kinase inhibitors, PPAR γ agonists, and vascular targeting agents are some of the latest therapeutic agents that have shown promise and could become standard of therapy with further supporting research. Summary Further well coordinated preclinical and clinical research is needed to support the emerging treatments for ATC.

Original languageEnglish (US)
Pages (from-to)387-391
Number of pages5
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume22
Issue number5
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Biological Factors
Aurora Kinases
Peroxisome Proliferator-Activated Receptors
Research
Blood Vessels
Thyroid Gland
Therapeutics
Retrospective Studies
Guidelines
Mutation
Mortality
Anaplastic Thyroid Carcinoma
Neoplasms

Keywords

  • anaplastic
  • anaplastic thyroid cancer
  • cancer
  • novel therapies
  • thyroid

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this

Anaplastic thyroid cancer. / Ranganath, Rohit; Shah, Manish A.; Shah, Ashok R.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 22, No. 5, 01.01.2015, p. 387-391.

Research output: Contribution to journalReview article

Ranganath, Rohit ; Shah, Manish A. ; Shah, Ashok R. / Anaplastic thyroid cancer. In: Current Opinion in Endocrinology, Diabetes and Obesity. 2015 ; Vol. 22, No. 5. pp. 387-391.
@article{e535633f728946e4bfe12a5e4f99b921,
title = "Anaplastic thyroid cancer",
abstract = "Purpose of review Anaplastic thyroid cancer (ATC) is a rare malignancy of the thyroid with a high mortality rate. Conventional therapy has not been effective. Several biological agents are being investigated. The purpose of the review is to highlight the current standards for treatment and review new targets for treating ATC. Recent findings Retrospective studies have led to formulation of guidelines for management, including those by the American Thyroid Association. An expansion in the understanding of the genetic mutations has led to several newer biological agents being tested to treat ATC. Aurora kinase inhibitors, PPAR γ agonists, and vascular targeting agents are some of the latest therapeutic agents that have shown promise and could become standard of therapy with further supporting research. Summary Further well coordinated preclinical and clinical research is needed to support the emerging treatments for ATC.",
keywords = "anaplastic, anaplastic thyroid cancer, cancer, novel therapies, thyroid",
author = "Rohit Ranganath and Shah, {Manish A.} and Shah, {Ashok R.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/MED.0000000000000189",
language = "English (US)",
volume = "22",
pages = "387--391",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Anaplastic thyroid cancer

AU - Ranganath, Rohit

AU - Shah, Manish A.

AU - Shah, Ashok R.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose of review Anaplastic thyroid cancer (ATC) is a rare malignancy of the thyroid with a high mortality rate. Conventional therapy has not been effective. Several biological agents are being investigated. The purpose of the review is to highlight the current standards for treatment and review new targets for treating ATC. Recent findings Retrospective studies have led to formulation of guidelines for management, including those by the American Thyroid Association. An expansion in the understanding of the genetic mutations has led to several newer biological agents being tested to treat ATC. Aurora kinase inhibitors, PPAR γ agonists, and vascular targeting agents are some of the latest therapeutic agents that have shown promise and could become standard of therapy with further supporting research. Summary Further well coordinated preclinical and clinical research is needed to support the emerging treatments for ATC.

AB - Purpose of review Anaplastic thyroid cancer (ATC) is a rare malignancy of the thyroid with a high mortality rate. Conventional therapy has not been effective. Several biological agents are being investigated. The purpose of the review is to highlight the current standards for treatment and review new targets for treating ATC. Recent findings Retrospective studies have led to formulation of guidelines for management, including those by the American Thyroid Association. An expansion in the understanding of the genetic mutations has led to several newer biological agents being tested to treat ATC. Aurora kinase inhibitors, PPAR γ agonists, and vascular targeting agents are some of the latest therapeutic agents that have shown promise and could become standard of therapy with further supporting research. Summary Further well coordinated preclinical and clinical research is needed to support the emerging treatments for ATC.

KW - anaplastic

KW - anaplastic thyroid cancer

KW - cancer

KW - novel therapies

KW - thyroid

UR - http://www.scopus.com/inward/record.url?scp=84960080304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960080304&partnerID=8YFLogxK

U2 - 10.1097/MED.0000000000000189

DO - 10.1097/MED.0000000000000189

M3 - Review article

C2 - 26313900

AN - SCOPUS:84960080304

VL - 22

SP - 387

EP - 391

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 5

ER -